Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Simes

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Applied Optics|June 18, 2010
Optically addressed spatial light modulators by MBE-grown nipi MQW structuresJ Maserjian, P O Andersson, B R Hancock, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 22, 2015
Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancerPenelope E Schofield, M R Stockler, D Zannino, et al.
Circulation|October 15, 1996
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trialH D White, G I Barbash, R M Califf, et al.
British Journal of Cancer|March 6, 2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerT J Price, M A Bruhn, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabN C Tebbutt, F Murphy, D Zannino, et al.
British Journal of Cancer|July 1, 2015
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancerA J Weickhardt, D S Williams, C K Lee, et al.
Lancet (London, England)|November 29, 2005
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialA Keech, R J Simes, P Barter, et al.
Trials|December 12, 2022
Approaches to prioritising research for clinical trial networks: a scoping reviewRachael L Morton, Haitham Tuffaha, Vendula Blaya-Novakova, et al.
European Heart Journal|May 15, 2007
Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2J J Edmond, J K French, P E G Aylward, et al.
BMC Cancer|March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaR Mercieca-Bebber, E H Barnes, K Wilson, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Applied Optics|June 18, 2010
Optically addressed spatial light modulators by MBE-grown nipi MQW structuresJ Maserjian, P O Andersson, B R Hancock, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 22, 2015
Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancerPenelope E Schofield, M R Stockler, D Zannino, et al.
Circulation|October 15, 1996
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trialH D White, G I Barbash, R M Califf, et al.
British Journal of Cancer|March 6, 2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerT J Price, M A Bruhn, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabN C Tebbutt, F Murphy, D Zannino, et al.
British Journal of Cancer|July 1, 2015
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancerA J Weickhardt, D S Williams, C K Lee, et al.
Lancet (London, England)|November 29, 2005
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialA Keech, R J Simes, P Barter, et al.
Trials|December 12, 2022
Approaches to prioritising research for clinical trial networks: a scoping reviewRachael L Morton, Haitham Tuffaha, Vendula Blaya-Novakova, et al.
European Heart Journal|May 15, 2007
Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2J J Edmond, J K French, P E G Aylward, et al.
BMC Cancer|March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaR Mercieca-Bebber, E H Barnes, K Wilson, et al.
Pageof 15